Anavex Life Sciences Corp (fra:12X1) Share Price

Company Profile

Business description
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Contact
630 5th Avenue
20th Floor
New YorkNY10111
USA
T: +1 844 689-3939
E: [email protected]
https://www.anavex.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
34

Recommended

We think this improves Nvidia’s position within the open-source community.

Brian Colello, CPA | 03 September 2026

Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.

Tom Lauricella | 03 September 2026

Elevated copper prices raise valuation questions.

Tyger Fitzpatrick | 02 September 2026

Index	Last price	Change	% Change
All Ordinaries	9,196.00	54.60	-0.59%
CAC 40	8,258.19	28.21	-0.34%
DAX 40	26,088.29	84.97	0.33%
Dow JONES (US)	53,686.11	624.16	1.18%
FTSE 100	10,802.02	29.50	-0.27%
HKSE	25,650.87	437.56	1.74%
NASDAQ	26,584.06	366.23	1.40%
Nikkei 225	65,020.94	806.46	1.26%
NZX 50 Index	13,974.18	128.00	0.92%
S&P 500	7,747.71	0.00	0.00%
S&P/ASX 200	9,005.90	64.30	-0.71%
SSE Composite Index	3,930.12	11.97	-0.30%